On July 15, 2014, Ames, Iowa-based animal vaccine producer, Harrisvaccines, was announced as the recipient of the 2014 World Pork Expo New Product Tour Producer’s Choice Award.

Sponsored by National Hog Farmer, this coveted award honors a product for its exceptional quality and unique technology. Harrisvaccines’ is proud to receive this honor for Porcine Epidemic Diarrhea Vaccine, RNA, the only PEDv available on the market today. This year, 30 products competed for the Producer’s Choice Award in the World Pork Expo New Product Tour and every Expo attendee had a chance to vote for their favorite product.

“Harrisvaccines is honored to be the recipient of this year’s Producer’s Choice Award,” said Dr. Hank Harris, President and CEO of Harrisvaccines. “It is an incredible achievement to have esteemed members of the industry recognize and award our vaccine for the significant impact it has had on the pork industry during this difficult PED disease outbreak.”

“This demonstrates how far our PEDv vaccine has come in such a short amount of time,” says Joel Harris, Head of Sales and Marketing for Harrisvaccines. “Our rapid response technology allowed us to produce a viable vaccine in August 2013, and less than one year later we proudly receive this award.”

Produced using Harrisvaccinces’ revolutionary SirraVaxSM RNA Particle technology, Porcine Epidemic Diarrhea Vaccine, RNA, has played a critical role in treating PEDv since it was first introduced in the United States in April 2013. Weeks after the virus was discovered, Harrisvaccines produced a working vaccine, which was sold via veterinary prescription, the company has since sold approximately 2 million doses. In June 2014, Harrisvaccines received conditional licensure from the United States Department of Agriculture (USDA) allowing the vaccine to be sold directly to the veterinarians and swine producers battling PEDV.

About Harrisvaccines
Headquartered in Ames, Iowa, Harrisvaccines focuses on revolutionizing animal health vaccines and enhancing productivity in the swine and livestock industries. Using state-of-the-art advanced molecular science, Harrisvaccines employs their unique SirraVaxSM RNA Particle (RP) technology platform to develop rapid-response, herd-specific products for animal diseases. To learn more about Harrisvaccines, visit www.harrisvaccines.com.

2014-07-29 / Source Go back